Skyrizi Injection, Solution
Product Images NDC 0074-4059

Product Visual Gallery

This gallery contains 134 technical images submitted to the FDA as part of the official labeling for Skyrizi (NDC 0074-4059). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Percent Of Adult Subjects With Active Psoriatic Arthritis Achieving Acr20 Responses In Trial Psa-1 Through Week 24 (Skyrizi 02)

Illustration of a Skyrizi injection pen showing labeled components including the green activator button, gray hand grips, inspection window, white needle sleeve, needle, and a dark gray cap with a note not to remove it until ready to inject.*

FDA Label Image

Skyrizi Single-dose Pen (Skyrizi 03)

Instructional illustration titled 'STEP 1' showing a hand reaching to take a rectangular box from a shelf, depicting the first step in handling or preparing the product Skyrizi by AbbVie Inc.*

FDA Label Image

Step 1 (Skyrizi 04)

Illustration showing step 2 of a procedure with a disposal container and components including a Skyrizi prefilled injector pen, an alcohol wipe, and cap, alongside an icon indicating hand washing.*

FDA Label Image

Step 2 (Skyrizi 05)

The diagram illustrates step 3 of an injection process, showing recommended injectable areas for a medication. The areas highlighted include the abdomen around the navel and the upper outer thighs on both legs. An inset shows a hand pinching a section of skin on the abdomen, indicating preparation for injection.*

FDA Label Image

Step 3 (Skyrizi 06)

An instructional illustration showing Step 4 of a process involving the Skyrizi injection device. The image highlights a close-up view of the device's mechanism, indicating a specific alignment or positioning action with arrows for guidance.*

FDA Label Image

Step 4 (Skyrizi 07)

Instructional diagram showing the proper injection angle for Skyrizi administration, indicating a 90-degree angle for subcutaneous injection into the abdomen or thigh. The image highlights arm and leg positions with a close-up of the injection site.*

FDA Label Image

Step 5 (Skyrizi 08)

An instructional illustration showing Step 6 of using a Skyrizi injection device. It depicts a hand holding the injector pressing down against the skin, with a timer icon indicating to hold for 15 seconds and a downward arrow symbolizing injection direction.*

FDA Label Image

Step 6 (Skyrizi 09)

An instructional illustration showing a hand holding a prefilled injector pen for Skyrizi. The diagram highlights Step 7, indicating to press the injector's button a second time to activate it, with a yellow indicator shown as part of the injection process.*

FDA Label Image

Step 7 (Skyrizi 0a)

An instructional illustration showing a hand holding a Skyrizi auto-injector pen with the needle end downward, positioned above a patient's skin. The other hand is pressing a cotton ball or gauze pad onto the skin below. A black arrow points upward from the skin to the injection site, indicating the injection direction or step sequence.*

FDA Label Image

Step 8 (Skyrizi 0b)

An instructional illustration showing step 9 of a process involving pressing the top of a grey and white sharps disposal container with a hand holding a capped syringe, demonstrating safe disposal of the syringe into the container.*

FDA Label Image

Step 9 (Skyrizi 0c)

FDA Label Image

Month (Skyrizi 0d)

An instructional diagram showing a Skyrizi prefilled syringe with and without its cardboard sleeve. Labels identify components including the finger grip, plunger rod, calibrated expiration date, needle cover, and needle guard covering after use, demonstrating proper handling steps.*

FDA Label Image

A Diagram Of A Diagramdescription Automatically Generated (Skyrizi 0e)

An instructional illustration labeled 'Step 1' showing a preparation tray with a syringe prefilled with medication, a small packet, and a close-up circle highlighting a powder substance. This diagram likely depicts the initial steps for preparing an injectable medication, such as Skyrizi, for administration.*

FDA Label Image

Step 1 (Skyrizi 0f)

Instructional illustration showing Step 2 of the process for preparing or administering Skyrizi, a medication by AbbVie Inc. The image depicts a hand holding a syringe and another hand holding the medication vial or device, indicating connection or assembly by an arrow pointing right.*

FDA Label Image

Step 2 (Skyrizi 10)

An instructional illustration labeled Step 3 demonstrating the recommended injectable areas for Skyrizi. The diagram shows a person’s lower back and upper thigh, with a marked yellow area indicating where injections can be administered. An inset close-up shows a hand in the injection position on the thigh.*

FDA Label Image

Step 3 (Skyrizi 11)

An instructional illustration showing Step 4 for using a syringe-like applicator. It depicts a hand holding the device with the instruction to 'Check liquid' inside it. This is part of a usage guide for Skyrizi 150 mg/mL injectable solution by AbbVie Inc.*

FDA Label Image

Step 4 (Skyrizi 12)

An instructional illustration showing Step 5 in a procedure. It depicts a hand holding a syringe with liquid, with an arrow indicating detachment of the syringe from a small attached component. The image suggests how to remove the syringe from this component during administration.*

FDA Label Image

Step 5 (Skyrizi 13)

An instructional diagram related to the injection of Skyrizi. It shows a hand holding a syringe at a 45-degree angle, indicating the proper injection angle, with a magnified view illustrating the angle measurement relative to the skin.*

FDA Label Image

Step 6 (Skyrizi 14)

Instructional illustration titled 'STEP 7' showing a hand holding a syringe at a 45-degree angle with the note 'Hold angle steady.' The image includes a close-up of the syringe's needle guard, indicating how to properly position the needle during administration.*

FDA Label Image

Step 7 (Skyrizi 15)

An instructional illustration depicting a hand holding a syringe above a disposal container, labeled as Step 8. The image suggests safe syringe disposal as part of medication administration steps, without showing any specific text or product branding.*

FDA Label Image

Step 8 (Skyrizi 16)

An instructional line drawing showing parts of a syringe for Skyrizi, including the plunger rod, finger grip, label with expiration date, needle cover, and needle guard covering the needle after use. This diagram illustrates the syringe components and safe needle handling.*

FDA Label Image

Skyrizi Single-dose Prefilled Syringe (Skyrizi 17)

An instructional illustration labeled Step 1 showing a sharps disposal container, two syringes, alcohol prep pads, and a magnified view of a hand holding an alcohol prep pad. It appears to depict preparation steps for an injection process.*

FDA Label Image

Step 1 (Skyrizi 18)

An instructional graphic explaining a full dose of Skyrizi, indicating that it equals two injections given one after the other.*

FDA Label Image

Step 2 (Skyrizi 19)

An instructional diagram titled 'Step 2' showing the recommended injectable areas on the front of the thighs and the abdomen below the waist for Skyrizi administration. The illustration includes arrows pointing to these areas and a close-up image of a hand applying a medication patch or injection with a dotted circle on the skin.*

FDA Label Image

Step 3 (Skyrizi 1a)

An instructional warning image advising to pick an injection site at least 1 inch away from the first site when using a second syringe and emphasizing not to inject into the same site.*

FDA Label Image

Step 4 (Skyrizi 1b)

An instructional illustration showing Step 3 for preparing a Skyrizi injection. It depicts a hand holding a syringe vertically with the instruction to "Check liquid" visible alongside the syringe, demonstrating the step to inspect the liquid inside before use.*

FDA Label Image

Step 5 (Skyrizi 1c)

Instructional diagram showing Step 4 of a process, where a hand is holding a syringe and an arrow indicates pulling the syringe cap off. The illustration highlights the action of removing the syringe cap before proceeding to the next step.*

FDA Label Image

Step 6 (Skyrizi 1d)

An instructional illustration showing a hand holding a syringe, with an inset detail emphasizing a 45-degree angle for injection. This appears to be part of a step-by-step guide for administering Skyrizi, a product by AbbVie Inc.*

FDA Label Image

Step 7 (Skyrizi 1e)

An instructional illustration showing Step 6 for administering an injection of Skyrizi. It depicts a hand holding a syringe at a steady 45-degree angle with a needle guard in place, directed towards an injection site on the abdomen. The image emphasizes maintaining the angle steady during injection.*

FDA Label Image

Step 8 (Skyrizi 1f)

Instructional graphic showing Step 7 of an injection process for Skyrizi. It indicates that 2 injections are required, with two syringe icons depicted.*

FDA Label Image

Step 1 (Skyrizi 20)

Illustration showing Step 8 of a process involving the use of a syringe. The image depicts a hand holding a syringe over a disposal container with a lid, guiding the syringe into the container, likely indicating safe disposal of the syringe.*

FDA Label Image

1 Full Dose (Skyrizi 21)

An instructional front view illustration of the Skyrizi on-body injector showing labeled parts: adhesive material, status light, gray start button with a warning not to touch until ready to inject, gray door with a notice not to close without the prefilled cartridge inside, medicine window, and pull tabs.*

FDA Label Image

Steep 2 (Skyrizi 22)

Illustration showing the back view of a Skyrizi device component, labeled with parts including a clear plastic strip, needle cover, adhesive backing, and two green pull tabs (small section and large section). Warnings indicate the needle is inside under the needle cover and caution not to touch the needle or needle cover.*

FDA Label Image

When Using The 2nd Syringe: (Skyrizi 23)

An instructional side view diagram illustrating the parts of a prefilled injector device for Skyrizi medication. It highlights the door latch, the gray door which should be slightly open, and warnings not to close the door without the prefilled cartridge inside. The needle cover and needle inside are indicated with cautions to avoid touching the needle cover or needle.*

FDA Label Image

Step 3 (Skyrizi 24)

An instructional diagram of a Skyrizi prefilled cartridge showing labeled parts including the larger prefilled cartridge top, white plunger, medicine chamber, and smaller bottom tip. It also indicates the location of the expiration date on the cartridge label.*

FDA Label Image

Step 4 (Skyrizi 25)

An instructional illustration labeled '1A' showing a hand pulling out a box from a shelf or storage unit and a calendar icon with a check mark, suggesting scheduling or timing instructions.*

FDA Label Image

Step 5 (Skyrizi 26)

An instructional illustration showing a timer set to 45 seconds, alongside a box representing the product packaging. This likely indicates a recommended wait or step duration related to the Skyrizi medication process.*

FDA Label Image

Step 6 (Skyrizi 27)

An instructional illustration showing how to open the box by lifting the top flap, indicated by a green arrow pointing upward. The image is associated with Skyrizi packaging instructions from AbbVie Inc.*

FDA Label Image

Step 7 (Skyrizi 28)

An instructional illustration showing a sharps container with a lid, a prefilled syringe, alcohol prep pads, and a cotton ball. It includes an icon depicting hand washing, indicating proper hygiene procedures related to injection or medication administration for Skyrizi.*

FDA Label Image

Step 8 (Skyrizi 29)

An instructional diagram showing a hand peeling back a tab or seal from a container. The image is marked with a blue label '1E' in the upper right corner. No branding or dosage information is visible.*

FDA Label Image

On-body Injector (Skyrizi 2a)

An instructional illustration showing a hand removing or lifting a component from a molded tray, indicated by a green arrow curving upwards. The image appears to guide the user on opening or accessing the product packaging or parts, with a blue label marked '1F' in the top right corner.*

FDA Label Image

Back View (Skyrizi 2b)

An instructional diagram showing front and back views of a medical device, likely an autoinjector. The front view highlights the gray door and start button. The back view cautions that the needle is inside under a needle cover, emphasizing safe handling.*

FDA Label Image

Side View (Skyrizi 2c)

Skyrizi 150 mg/mL solution for injection carton and vial label from AbbVie Inc. The packaging includes a box showing product name and strength with a vial containing clear liquid displayed beside it. The vial is labeled with concentration and brand name.*

FDA Label Image

Prefilled Cartridge (Skyrizi 2d)

An instructional diagram showing the back view of a Skyrizi autoinjector. It highlights a gray door being opened and a needle visibly positioned inside under the needle cover. The illustration guides users on how to access the needle cover before injection.*

FDA Label Image

1a (Skyrizi 2e)

Illustration showing a hand holding a Skyrizi prefilled cartridge highlighting the larger top tip and smaller bottom tip, indicating correct cartridge orientation for administration.*

FDA Label Image

1b (Skyrizi 2f)

Illustration for Skyrizi injection showing a two-step process: holding the injector with the smaller bottom tip pointing down, and cleaning the center of this smaller bottom tip with an antiseptic wipe, as part of preparation before administration.*

FDA Label Image

1c (Skyrizi 30)

An instructional illustration demonstrating how to insert the Straight 2D injection pen needle into a Skyrizi autoinjector device. It shows a hand positioning the needle straight down onto the pen with an arrow indicating insertion, and a close-up inset indicating a 'click' sound on successful attachment.*

FDA Label Image

1d (Skyrizi 31)

An instructional illustration showing a hand pressing down on the cap of a device with an arrow and the word "snap" indicating the cap is being removed or attached. The device likely relates to the Skyrizi product, manufactured by AbbVie Inc., but no drug-specific details are visible.*

FDA Label Image

1e (Skyrizi 32)

An instructional illustration showing recommended injection sites on a human body for Skyrizi. Green highlighted areas include the abdomen around the navel and the front of the thighs. The diagram is labeled with '3A' in the top right corner.*

FDA Label Image

1f (Skyrizi 33)

An instructional diagram showing a hand gripping and twisting a blue cap with arrows indicating a twisting motion, positioned above the waistband of pants. The illustration is labeled with '3B' in the upper right corner, suggesting a step in a usage or assembly instruction related to the product Skyrizi by AbbVie Inc.*

FDA Label Image

Do Not Touch The Gray Start Button (Skyrizi 34)

An instructional diagram showing how to remove adhesives by peeling apart small and large sections to reveal the needle inside an activated injector. The image also displays a status light flashing blue on the injector accompanied by a "beep-beep-beep" sound indicator, illustrating proper activation steps for a Skyrizi injector device.*

FDA Label Image

1g (Skyrizi 35)

A safety instruction panel for the Skyrizi On-Body Injector. It advises users that if the status light flashes red and beeps are heard, the injector is malfunctioning and should not be used. It provides contact phone numbers for assistance and instructions to carefully remove the injector from the skin if attached.*

FDA Label Image

Do Not Touch The Gray (Skyrizi 36)

Instructional illustration showing recommended injection sites for Skyrizi. The top panel demonstrates the abdomen area (belly) with directional arrows, while the bottom panel highlights the thigh area, both marked with dotted green lines to indicate injection zones.*

FDA Label Image

2a (Skyrizi 37)

An instructional illustration showing a hand pressing firmly on a Skyrizi injection device. The illustration includes a green arrow pointing left to right, indicating the direction to press firmly on the device, which is part of the self-administration process.*

FDA Label Image

Avoid Touching The Needle Cover (Skyrizi 38)

Illustration showing how to prepare the Skyrizi autoinjector for use. The image depicts a hand pressing on the device, with visual and audible cues indicated by a 'click' sound and a 'beep-beep-beep' to signal activation.*

FDA Label Image

2b (Skyrizi 39)

Instructional illustration showing a Skyrizi injection device secured in a holder or pocket. A timer icon with the number 5 and a green progress segment indicates to wait five minutes. A green-lit button detail on the device is highlighted, suggesting activation or readiness for use.*

FDA Label Image

2c (Skyrizi 3a)

An instructional illustration showing a close-up of a device button highlighted in green, indicating it emits a 'beep-beep-beep' sound. The image likely depicts a step in using a Skyrizi injection device by AbbVie Inc.*

FDA Label Image

2d (Skyrizi 3b)

An instructional diagram showing a person holding a Skyrizi prefilled syringe or autoinjector, with a green arrow indicating a step in the injection process. A bubble with the text 'beep-beep-beep' suggests an audio cue from the device during use.*

FDA Label Image

Do Not Twist Or Remove (Skyrizi 3c)

An instructional illustration showing a hand holding a Skyrizi autoinjector pen, positioned to administer the injection. A separate inset displays a capsule or pill shape, likely indicating the medicine form or part of the device. The image is labeled with '5A' in the top right corner.*

FDA Label Image

Caution Symbol (Skyrizi 3d)

An instructional illustration showing a hand disposing of a used syringe into a sharps container. The container is labeled 'Sharps Container' and has a secure lid to safely hold the disposed syringe.*

FDA Label Image

2e (Skyrizi 3e)

A symbol key chart explaining the meanings of indicator lights and symbols for the Skyrizi On-Body Injector. It includes caution sign, flashing blue light (On/Ready), flashing green light (Injection has started), solid green light (Injection has finished), no light (Off/Finished), and flashing red light indicating the device is not working and directs users to call specified phone numbers.*

FDA Label Image

Do Not Close The Gray Door (Skyrizi 3f)

Skyrizi 150 mg/mL solution for injection in a clear vial with a purple cap, manufactured by AbbVie Inc. The vial is labeled 'STERILE EO' indicating sterilization method. The product name Skyrizi and concentration 150 mg/mL are prominently displayed on the label.*

FDA Label Image

3a (Skyrizi 40)

FDA Label Image

3b (Skyrizi 41)

A small label with the text 'STERILE' and 'EO' separated by a vertical line, indicating that the product is sterilized using ethylene oxide. No additional product-specific information is visible in the image.*

FDA Label Image

3c (Skyrizi 42)

FDA Label Image

Turn The On-body Injector (Skyrizi 43)

FDA Label Image

If The Status Light Flashes Red, And Beeps (Skyrizi 44)

FDA Label Image

3d (Skyrizi 45)

The image shows a rectangular black border with the bold, uppercase text "LOT" centered inside. This label likely represents a lot or batch number identifier, commonly found on pharmaceutical packaging such as that for Skyrizi by AbbVie Inc.*

FDA Label Image

3e (Skyrizi 46)

FDA Label Image

4a (Skyrizi 47)

FDA Label Image

Do Not Touch The (Skyrizi 48)

FDA Label Image

4b (Skyrizi 49)

FDA Label Image

4c (Skyrizi 4a)

FDA Label Image

4d (Skyrizi 4b)

Packaging label for Skyrizi 150 mg/mL solution for injection supplied by AbbVie Inc. The label shows the product name, strength, and includes detailed instructions with illustrations on how to use the Skyrizi-Pen. The packaging design features a blue and white theme with a red accent line and space for a pharmacy label and barcode.*

FDA Label Image

Avoid Touching The Needle (Skyrizi 4c)

Packaging label for Skyrizi 150 mg/mL injection from AbbVie Inc. The label includes the proprietary name Skyrizi, the strength 150 mg/mL, and detailed instructions for use. The design features a blue sky background with clouds. The label also contains information about the contents and usage directions on the side panels.*

FDA Label Image

5a (Skyrizi 4d)

Packaging label for Skyrizi 150 mg/mL injection by AbbVie Inc. The label features a blue sky background with white clouds and includes the proprietary name Skyrizi, the strength 150 mg/mL, the generic name risankizumab-rzaa, and Rx only designation. It also shows areas for pharmacy label and barcode information, with illustrated instructions for injection preparation and administration on the side panel.*

FDA Label Image

If The Used White Plunger (Skyrizi 4e)

Skyrizi 150 mg/mL injection carton from AbbVie Inc. The label includes the proprietary name, active ingredient risankizumab-rzaa, strength 150 mg/mL, and basic product information. The packaging also features step-by-step instructions with illustrations for preparing and administering the injection using a prefilled syringe. The design incorporates blue and white colors with branding elements and regulatory text.*

FDA Label Image

5b (Skyrizi 4f)

Skyrizi (risankizumab-rzaa) injection packaging label from AbbVie Inc. The label includes multiple strength options noted in the product data and contains detailed instructions for use. The design features predominantly blue and white colors with black text and includes spaces designated for pharmacy labeling and product information.*

FDA Label Image

Symbol Key (Skyrizi 50)

The image shows the packaging label for Skyrizi 150 mg/mL injection, a single-dose prefilled syringe containing risankizumab-rzaa. The label is primarily blue and white with red accents and includes detailed usage instructions with illustrations. It is labeled for prescription use only and produced by AbbVie Inc.*

FDA Label Image

Sterilized (Skyrizi 51)

Packaging label for Skyrizi 150 mg/mL injection by AbbVie Inc., featuring an unfolded carton layout. The label includes dosing instructions, product name with strength, active ingredient risankizumab-rzaa, barcode, and safety warnings. The design uses a blue and white color scheme with text in English.*

FDA Label Image

Keep Dry (Skyrizi 52)

Packaging label for Skyrizi 150 mg/mL injection by AbbVie Inc. The label includes product name, active ingredient risankizumab-rzaa, dosage strength, a single-dose prefilled syringe, safety and preparation instructions, warnings, and manufacturer details. The design features blue and white colors with highlighted cautionary information and usage steps.*

FDA Label Image

Sterilized Using Ethylene Oxide (Skyrizi 53)

Skyrizi 150 mg/mL injection carton label showing a 1 x 2.4 mL prefilled cartridge with a 1-on-body injector. The label includes dosage strength of 360 mg/2.4 mL, active ingredient risankizumab-rzaa, usage instructions, storage warnings, and manufacturer AbbVie Inc. It also features a medication guide insert and cautions about not freezing or shaking the product.*

FDA Label Image

Do Not Re-use (Skyrizi 54)

Packaging label for Skyrizi 150 mg/2.4 mL (150 mg/mL) prefilled cartridge injection by AbbVie Inc. The carton includes patient and usage instructions, a blue and white color scheme, a photo of the on-body injector device, and safety and storage information. It states 'Rx only' and highlights the contents as a single-dose prefilled cartridge for subcutaneous use.*

FDA Label Image

Do Not Use If Package Is Damanged And Consult (Skyrizi 55)

Label for Skyrizi injection, risankizumab-rzaa, 600 mg/10 mL (60 mg/mL) strength, for intravenous use only. The label states it is a single-dose vial and must be diluted prior to use. Manufactured by AbbVie Inc., North Chicago, IL, with storage instructions to refrigerate and protect from light. The label includes a barcode and Rx Only designation.*

FDA Label Image

Date Of Manufacture (Skyrizi 56)

Packaging label for Skyrizi 600 mg/10 mL (60 mg/mL) injection by AbbVie Inc. The label indicates the product is for intravenous use only, requiring dilution before use. It comes as a single-dose 10 mL vial and includes storage instructions to refrigerate between 2°C to 8°C. The label includes warnings, ingredients, and manufacturer information with a barcode and US license number.*

FDA Label Image

Batch Code (Skyrizi 57)

The image shows a black and white label with the text 'LOT' inside a rectangular box, indicating a lot number field commonly used on pharmaceutical packaging.*

FDA Label Image

Catalogue Number (Skyrizi 58)

FDA Label Image

Serial Number (Skyrizi 59)

FDA Label Image

Refer To Instruction Manual (Skyrizi 5a)

An instructional diagram showing a person reading a document or instructions. The illustration emphasizes the importance of reviewing written information, likely related to medication usage or guidelines.*

FDA Label Image

Type Bf Applied Part (Skyrizi 5b)

FDA Label Image

Mr Unsafe (Skyrizi 5c)

FDA Label Image

1 Full Induction Dose (Skyrizi 5d)

An instructional illustration showing that 1 Full Induction Dose of Skyrizi consists of 2 On-Body Injectors, each containing 2 prefilled cartridges. The diagram emphasizes that both injectors are required to complete the full induction dose.*

FDA Label Image

A Purple And White Sign With Black Textai-generated Content May Be Incorrect. (Skyrizi 5e)

An instructional graphic illustrating the full induction dose of Skyrizi, showing two on-body injector devices required for one full dose. The image emphasizes that two on-body injections are necessary for a complete dose.*

FDA Label Image

1a (Skyrizi 5f)

An instructional illustration showing a hand placing a box labeled '1A' into a refrigerator. A calendar icon with a checkmark is shown in the lower corner, suggesting a step related to timing or scheduling for product storage or use.*

FDA Label Image

A White Box With A Black And Green Clockai-generated Content May Be Incorrect. (Skyrizi 60)

An instructional diagram showing a box with a timer graphic indicating 45 seconds. The image appears to demonstrate a waiting or preparation time.*

FDA Label Image

A White Box With Green Arrow Pointing To The Topai-generated Content May Be Incorrect. (Skyrizi 61)

Instructional illustration showing the opening of a box by lifting the top flap, labeled '1C', likely part of packaging or usage instructions for Skyrizi by AbbVie Inc.*

FDA Label Image

A Container With A Lid And A Bucket With A Lidai-generated Content May Be Incorrect. (Skyrizi 62)

An instructional illustration showing a sharps container and multiple syringe-like devices positioned nearby. It also includes an icon indicating handwashing, suggesting a hygiene step in the procedure.*

FDA Label Image

Do Not Touch (Skyrizi 63)

A text instruction panel containing a warning note that advises not to touch the gray start button until it is time to inject and states the button can be pressed only once. The text is in black and highlighted by a yellow triangle with an exclamation mark, indicating caution.*

FDA Label Image

A Hand Holding A Cameraai-generated Content May Be Incorrect. (Skyrizi 64)

An instructional illustration showing front and back views of a Skyrizi prefilled injection device. The front view highlights the gray door and start button, while the back view indicates the position of the needle inside under the needle cover. The device is held in a hand for scale.*

FDA Label Image

Do Not Touch (Skyrizi 65)

This text panel provides a usage warning for Skyrizi injection, instructing users not to press the gray start button on the device more than once and to avoid pressing it before placing it on the body. It includes contact information for support from the labeler AbbVie Inc.*

FDA Label Image

Repeat Steps 2a (4A for each injection)

Instructional note indicating to repeat Steps 2A through 4A for each injection, using one On-Body Injector for each injection. The text is displayed on a red background with a white dashed border.*

FDA Label Image

A Diagram Of A Machineai-generated Content May Be Incorrect. (Skyrizi 67)

An instructional diagram showing the back view of a Skyrizi injection pen with a gray door being opened by a hand. It highlights the needle cover and indicates the needle is inside, beneath the needle cover, to assist users in proper preparation for injection.*

FDA Label Image

Avoid Touching The Needle Cover (Skyrizi 68)

A cautionary instruction panel advising to avoid touching the needle cover or the needle on the back of the On-Body Injector, noting the needle is located behind the needle cover.*

FDA Label Image

Do Not Touch The Gray Start (Skyrizi 69)

This image contains a medication instruction warning stating: 'Do not touch the gray start button until it is time to inject. It can be pressed 1-time only.' It also advises to put the On-Body Injector aside after use. The text highlights proper use instructions related to injection timing and device handling.*

FDA Label Image

Do Not Twist Or Remove The Larger (Skyrizi 6a)

This text panel provides instructions on how to properly insert and secure the prefilled cartridge into the On-Body Injector for the medication Skyrizi by AbbVie Inc. It includes warnings about not twisting or removing the cartridge top, when to press the injection button, and notes on fully inserting the cartridge with audible confirmation.*

FDA Label Image

Make Sure That You Start The Injection Within (Skyrizi 6b)

A warning label instructing users to start the injection within 5 minutes after inserting the prefilled cartridge into the On-Body Injector. It cautions that delay may dry out the medicine and cause the On-Body Injector to malfunction.*

FDA Label Image

Do Not Close The Gray Door (Skyrizi 6c)

Instructional text providing detailed steps and warnings for handling the gray door and start button on a device with a prefilled cartridge, focusing on ensuring proper cartridge insertion and device operation before injection.*

FDA Label Image

3c (Skyrizi 6d)

An instructional diagram for an activated injector showing the step to expose adhesives by peeling back small and large sections to reveal the needle inside (under needle cover). It also depicts the status light flashing blue on the injector alongside a beep-beep-beep sound indicator.*

FDA Label Image

Turn The On-body Injector Over (Skyrizi 6e)

A text panel with instructions for using an on-body injector device, including a warning to avoid touching the needle cover or needle. It also advises turning the injector over to locate green pull tabs. No specific product name or dosage information is shown in the image.*

FDA Label Image

Do Not Press The Gray Start (Skyrizi 6f)

A partial instructional text panel with warnings advising not to press the gray start button and not to touch the needle cover or the needle, likely related to safe handling or administration of the Skyrizi injection.*

FDA Label Image

Do Not Touch The Gray Start (Skyrizi 70)

An instructional text panel advising users not to touch the gray start button on the On-Body Injector until the prefilled cartridge is placed on the skin and ready to inject, emphasizing that the start button can only be pressed once.*

FDA Label Image

A Red And White Sign With Black Textai-generated Content May Be Incorrect. (Skyrizi 71)

Instructional text panel for Skyrizi injection explaining steps to repeat a procedure for the second injection, specifically referencing Step 2A to 4A and continuing to Step 4B once the second injector is activated.*

FDA Label Image

Avoid Touching The Needle Cover (Skyrizi 72)

A safety warning panel for Skyrizi On-Body Injector cautioning users to avoid touching the needle cover or needle on the back of the injector. The panel includes a warning symbol and clear safety instructions.*

FDA Label Image

If The Used White Plunger Does Not (Skyrizi 73)

A warning message panel instructing users to call (866) SKYRIZI or (866) 759-7494 if the used white plunger does not fill the window, related to Skyrizi medication usage or administration instructions.*

FDA Label Image

If You Only Completed 1 Injection (Skyrizi 74)

A red and white instructional text panel from Skyrizi packaging, advising to repeat specific injection steps if only one injection was completed, and to continue to a subsequent step once the second injector is activated.*

FDA Label Image

On-body Injector Sterilized Using Ethylene Oxide. (Skyrizi 75)

The image shows a pharmaceutical vial labeled Skyrizi, manufactured by AbbVie Inc. The vial packaging displays the brand name 'Skyrizi' prominently along with drug concentration information, including 150 mg/mL, 180 mg/1.2mL, 55 mg/0.37mL, and 600 mg/10mL strengths, indicating multiple dose presentations. The label includes typical vial markings and sterile indication.*

FDA Label Image

Ndc 0074-2100-01one 1 mL Single-dose Prefilled Penskyrizi® Pen 150 mg/mlrisankizumab-rzaa Injection For Subcutaneous Use Onlyreturn To Pharmacy If Carton Perforations Are Broken.attention Pharmacist:each Patient Is Required To Receive The Enclosed Medication Guide.the Entire Carton Is To Be Dispensed As A Unit.www.skyrizi.comrx Onlyabbvie (Skyrizi 76)

Skyrizi 150 mg/mL single-dose prefilled pen carton label by AbbVie Inc. The label indicates a 1 mL sterile single-dose pen containing 150 mg Risankizumab-rzaa with additional inactive ingredients listed. It includes instructions to return the carton to the pharmacy and notes the product is prescription-only, manufactured by AbbVie Inc. in the USA and Germany.*

FDA Label Image

One 1 mL Single-dose Prefilled Syringeskyrizi® 150 mg/mlrisankizumab-rzaa Injection For Subcutaneous Use Onlyarea For Pharmacy Labelwww.skyrizi.comrx Onlyabbvie (Skyrizi 77)

Skyrizi 150 mg/mL prefilled syringe packaging label by AbbVie Inc. The label includes the proprietary name Skyrizi, active ingredient risankizumab-rzaa, strength 150 mg/mL, and specifies injection for subcutaneous use only. It lists ingredients in the 1 mL syringe and states the product is preservative-free. The carton also shows usage instructions, manufacturer information, and an area marked for pharmacy labels.*

FDA Label Image

Ndc 0074-1070-01 1 X 2.4 mL Prefilled Cartridge1 On-body Injectorskyrizi®risankizumab-rzaa Injection 360 mg/2.4 mL(150 mg/ml)for Subcutaneous Use Only Single-doseskyrizi.comrx Onlyabbvie (Skyrizi 78)

Skyrizi 360 mg/2.4 mL (150 mg/mL) risankizumab-rzaa injection prefilled cartridge and on-body injector packaging label by AbbVie Inc. The label shows the dose, administration route (subcutaneous), and that it is single-dose. It includes ingredient details and carton contents, alongside an image of the on-body injector device.*

FDA Label Image

Ndc 0074-1084-012 X 2.4 mL Single-dose Prefilled Cartridges2 Single-dose On-body Injectorsskyrizi®risankizumab-rzaa Injection 360 mg/2.4 mL Per On-body Injectorsfor A Full 720 mg Induction Dosefor Subcutaneous Use Only Induction Pack For Crohn’s Diseaseone Pack Contains One Dose Of The Required Fourinduction Doses.the Entire Carton Is To Be Dispenses As A Unit.attention Pharmacist:each Patient Is Required To Receive The Enclosedmedication Guide.when You Are Ready To Use, Removecarton From Refrigerator, And Leavecarton At Room Temperature For45 Minutes To Allow To Warm.skyrizi.comrx Onlyabbvie (Skyrizi 79)

Skyrizi 360 mg/2.4 mL per on-body injector, injection label for risankizumab-rzaa. The label indicates a pack containing 2 single-dose on-body injectors for a total 720 mg induction dose, designed for subcutaneous use only. The packaging is marked as an induction pack for Crohn's Disease by AbbVie Inc., with instructions for storage and use at room temperature for 45 minutes before application.*

FDA Label Image

Ndc 0074-5015-01 Skyrizi®risankizumab-rzaa Injection 600 mg/10 mL(60 mg/ml)for Intravenous Use Only Must Be Diluted Prior To Useone 10 mL Single-dose Vial-discard Unused Portionattention: Dispense The Enclosed Medication Guide To Each Patient.rx Onlyabbvie (Skyrizi 7a)

Skyrizi 600 mg/10 mL (60 mg/mL) injection vial label. The label shows the proprietary name Skyrizi with the active ingredient risankizumab-rzaa, intended for intravenous use only and must be diluted prior to use. Each 10 mL vial contains 600 mg of risankizumab-rzaa. Storage instructions specify refrigeration at 36°F to 46°F (2°C to 8°C) protected from light. The label includes warnings for single use only, disposal of unused portions, and absence of preservatives. Manufactured by AbbVie Inc., North Chicago, IL 60064, USA. Features include the US license number 1889, GTIN barcode, and the AbbVie logo.*

FDA Label Image

Ndc 0074-1069-01skyrizi®risankizumab-rzaainjection360 mg/2.4 mL(150 mg/ml)for Subcutaneous Use Onlysingle-doserx Only (Skyrizi 7b)

Label for Skyrizi risankizumab-rzaa injection, showing a strength of 360 mg/2.4 mL (150 mg/mL). The label includes dosage form as injection, single-dose for subcutaneous use only. Manufactured by AbbVie Inc., North Chicago, IL, USA. The label also displays the NDC 0074-1069-01 and a barcode with a QR code.*

FDA Label Image

Ndc 0074-7032-90one 1 mL Single-dose Prefilled Syringeskyrizi®risankizumab-rzaa Injection 90 mg/mlfor Subcutaneous Use Onlyfor Healthcare Provider Administration Onlywww. Skyrizi.comrx Onlyabbvie (Skyrizi 7c)

FDA Label Image

Ndc 0074-1065-01 1 X 1.2 mL Prefilled Cartridge1 On-body Injectorskyrizi®risankizumab-rzaa Injection 180 mg/1.2 mL(150 mg/ml)for Subcutaneous Use Only Single-doseskyrizi.comrx Onlyabbvie (Skyrizi 7d)

Skyrizi 180 mg/1.2 mL (150 mg/mL) injection by AbbVie Inc. The label is for a single-dose prefilled cartridge with an on-body injector for subcutaneous use. The carton lists active and inactive ingredients and includes one prefilled cartridge, one on-body injector, a package insert, and instructions for use.*

FDA Label Image

Ndc 0074-1066-01skyrizi®risankizumab-rzaainjection180 mg/1.2 mL(150 mg/ml)for Subcutaneous Use Onlysingle-doserx Only (Skyrizi 7e)

Label for Skyrizi 180 mg/1.2 mL (150 mg/mL) injection, containing the active ingredient risankizumab-rzaa. It is for subcutaneous use only, single-dose, and prescription use. Manufactured by AbbVie Inc., North Chicago, IL, USA. The label shows NDC 0074-1066-01, a barcode, a QR code, and the U.S. License No. 1889.*

FDA Label Image

Ndc 0074-1066-02not For Saleskyrizi®risankizumab-rzaainjection180 mg/1.2 mL(150 mg/ml)for Subcutaneous Use Onlysingle-doserx Only (Skyrizi 7f)

Label for Skyrizi 180 mg/1.2 mL injection, containing risankizumab-rzaa. It is for subcutaneous use only, single-dose, and prescription use. The label includes the NDC number 0074-1066-02 and identifies AbbVie Inc., North Chicago, IL, as the manufacturer. A QR code and barcode are also visible.*

FDA Label Image

Ndc 0074-7034-022 X 1 mL Prefilled Syringesskyrizi®risankizumab-rzaa Injection 90 mg/ml Per Syringe2 X 90 mg/ml. Single-dose Prefilledsyringes For A Total 180 mg/2 mL Dosefor Subcutaneous Use Onlyfor Healthcare Provider Administration Onlywww. Skyrizi.comrx Onlyabbvie (Skyrizi 80)

FDA Label Image

Ndc 0074-7036-044 X 1 mL Prefilled Syringesskyrizi®risankizumab-rzaa Injection 90 mg/ml Per Syringe4 X 90 mg/ml Single-dose Prefilledsyringes For A Total 360 mg/4 mL Dosefor Subcutaneous Use Onlyfor Healthcare Provider Administration Onlyattention Pharmacist:each Patient Is Required To Receive The Enclosed Medication Guide. The Entire Carton Is To Be Dispensed As A Unit. Return To Pharmacy If Carton Seal Is Broken Or Missing. Www. Skyrizi.comrx Onlyabbvie (Skyrizi 81)

FDA Label Image

Ndc 0074-7032-01skyrizi® 90 mg/mlrisankizumab-rzaainjectionfor Subcutaneous Use Onlyfor Healthcare Provider Administration Onlyfor A 350 mg Does,four 90 mg Syringes Are Required,inject All 4 Syringes For A Full Dosewww.skyrizi.comrx Onlyabbvie (Skyrizi 82)

FDA Label Image

Ndc 0074-7040-02 2 X 90 mg/ml Single Dose Prefilled Syringesskyrizi®90 mg/ml Per Syringe2 X 90 mg/ml Single-dose Prefilledsyringes For A Total 180 mg/2 mL Doserisankizumab-rzaainjection For Subcutaneous Use Onlyreturn To Pharmacy If Cartonperforations Are Broken.attention Pharmacist:each Patient Is Required To Receive The Enclosed Medication Guide.the Entire Carton Is To Bedispensed As A Unit.for A 180 mg Dose,two 90 mg Syringes Are Required.inject 2 Syringes For A Full Dose.www.skyrizi.comrx Onlyabbvie (Skyrizi 83)

Skyrizi 90 mg/mL prefilled syringe carton containing 2 single-dose prefilled syringes, each with 90 mg risankizumab-rzaa injection for subcutaneous use. The label highlights that two 90 mg syringes are required for a 180 mg dose. The product is labeled for prescription use only and distributed by AbbVie Inc.*

FDA Label Image

Ndc 0074-7042-04 4 X 90 mg/ml Single Dose Prefilled Syringesskyrizi®90 mg/ml Per Syringe4 X 90 mg/ml Single-dose Prefilledsyringes For A Total 360 mg/4 mL Doserisankizumab-rzaa Injectionfor Subcutaneous Use Onlyreturn To Pharmacy If Carton Perforations Are Broken.attention Pharmacist:each Patient Is Required To Receive Theenclosed Medication Guide.the Entire Carton Is To Be Dispensed As A Unit.for A 360 mg Dose,four 90 mg Syringes Are Required.inject All 4 Syringes For A Full Dose.www.skyrizi.comrx Onlyabbvie (Skyrizi 84)

Packaging label for Skyrizi 90 mg/mL injection, containing 4 single-dose prefilled syringes, each with 90 mg/mL of risankizumab-rzaa for subcutaneous use. The label instructs that four syringes are required for a full 360 mg dose. Manufactured by AbbVie Inc. The label includes usage directions and pharmacist instructions.*

FDA Label Image

Ndc 0074-8300-01one 1.2 mL Single -dose Prefilled Syringeskyrizi®180 mg/1.2 mL (150 mg/ml)risankizumab-rzaa Injectionfor Subcutaneous Use Onlyreturn To Pharmacy If Carton Perforations Are Broken.attention Pharmacist:each Patient Is Required To Receive Theenclosed Medication Guide.the Entire Carton Is To Be Dispensed As A Unit.www.skyrizi.comrx Onlyabbvie (Skyrizi 85)

Skyrizi 180 mg/1.2 mL (150 mg/mL) risankizumab-rzaa injection carton label for a single-dose prefilled syringe. The label includes dosage strength, administration route (subcutaneous use only), manufacturer AbbVie Inc., and important dispensing instructions for pharmacists. The packaging is primarily blue with white and a wave design accent.*

FDA Label Image

Ndc 0074-8350-01two 1.2 mL Single -dose Prefilled Syringesskyrizi®180 mg/1.2 mL (150 mg/ml) Per Syringe2 X 180 mg/1.2 mL Single Dose Prefilled Syringes For A Total 360 mg/2.4 mLrisankizumab-rzaa Injectionfor Subcutaneous Use Onlyfor A 360 mg Dose, Two 180 mg Syringes Are Required. Inject 2 Syringes For A Full Dose. Return To Pharmacy If Carton Perforations Are Broken.attention Pharmacist:each Patient Is Required To Receive Theenclosed Medication Guide.the Entire Carton Is To Be Dispensed As A Unit.www.skyrizi.comrx Onlyabbvie (Skyrizi 86)

Skyrizi 180 mg/1.2 mL prefilled syringe carton label showing 2 single-dose prefilled syringes, each containing 180 mg/1.2 mL risankizumab-rzaa injection for subcutaneous use. The label includes dosage instructions for a 360 mg dose requiring two syringes, manufacturer AbbVie Inc., and safety information for pharmacists to dispense the entire carton as a unit.*

FDA Label Image

Ndc 0074-4059-01one 0.37 mL Single-dose Prefilled Syringeskyrizi® 55mg mg/0.37 mLrisankizumab-rzaainjectionfor Subcutaneous Use Onlywww.skyrizi.comfor Children And Adolescents Less Than 40kg (88lb)return To Pharmacy If Carton Perforations Are Broken.attention Pharmacist:each Patient Is Required To Receive The Enclosed Medication Guide.the Entire Carton Is To Be Dispensed As A Unit.rx Onlyabbvie (Skyrizi 87)

Skyrizi 55 mg/0.37 mL prefilled syringe label for risankizumab-rzaa injection, intended for subcutaneous use and for children and adolescents less than 40 kg. The label includes a syringe image, dosing information, NDC 0074-4059-01, AbbVie Inc. as the labeler, and usage warnings including pharmacy return instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.